Stockreport

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELE [Read more]